[The effect of vilozen on the immune status of erysipelas patients and the prospects for its use for the immune rehabilitation of convalescents].
Frolov
V M
VM
Peresadin
N A
NA
Pinskiĭ
L L
LL
Korobka
Iu N
IuN
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000917:Antibody Formation / Q000187:drug effects; D001205:Ascorbic Acid / Q000627:therapeutic use; D003289:Convalescence; D004338:Drug Combinations; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D004886:Erysipelas / Q000188:drug therapy* / Q000276:immunology / Q000534:rehabilitation; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008875:Middle Aged; D012431:Rutin / Q000627:therapeutic use; D013949:Thymus Extracts / Q000627:therapeutic use*
D000276:Adjuvants, Immunologic; D000900:Anti-Bacterial Agents; D004338:Drug Combinations; D013949:Thymus Extracts; C044488:ascorbic acid, rutoside drug combination; C059606:iilozen; D012431:Rutin; D001205:Ascorbic Acid
Vliianie vilozena na immunnyĭ status bol'nykh rozheĭ i perspektivy ego ispol'zovaniia dlia immunoreabilitatsii rekonvalestsentov.